Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics

Medical Clinics of North America

Volumn 85, Issue 1, 2001, Pages 1-17

  Paradisi, Franco ^b   Corti, Giampaolo ^b   Messeri, Daniela ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

6 DEOXY 7 DIMETHYLAMINO 9 (N,N DIMETHYLGLYCINAMIDO) 6 NORTETRACYCLINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEPHALOSPORIN; CL 331002; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; EVERNIMICIN; EVERNINOMICIN; GLYCOPEPTIDE; GLYCYLCYCLINE DERIVATIVE; LINCOSAMIDE; LINEZOLID; MACROLIDE; METICILLIN; MINOCYCLINE; NAFCILLIN; ORITAVANCIN; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOGRAMIN; TEICOPLANIN; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SENSITIVITY; HUMAN; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 0035160063     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(05)70302-3     Document Type: Article

References (79)

1. Staphylococcus epidermidis and other coagulase-negative staphylococci
2. Antimicrobial susceptibility of coagulase-negative staphylococci
3. Conjugative transfer genes in staphylococcal isolates from the United States
4. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin
5. Outcomes with linezolid (LZD) from an ongoing compassionate use (CU) trials of patients (Pts) with significant, resistant, gram-positive infections
6. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin
7. Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci
8. Methicillin resistance in staphylococci: Molecular and biochemical basis and clinical implications
9. Adherence of slime-producing strains of Staphylococcus epidermidis to smooth surfaces
10. Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States
11. Resistance of staphylococci in the Netherlands: Surveillance by an electronic network during 1989-1995
12. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
13. Hospital-acquired pneumonia: Methicillin resistance and intensive care unit admission
14. Staphylococcus epidermidis extracted slime inhibits the antimicrobial action of glycopeptide antibiotics
15. Changing patterns of resistance of certain common pathogenic bacteria to antimicrobial agents
16. Guidelines for the control of methicillin-resistant Staphylococcus aureus
17. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2
18. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50
19. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin
20. Evaluation of bactericidal activities of LY 333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods
21. The positive predictive value of isolating coagulase negative staphylococci from blood cultures
22. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
23. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin MMWR, Morb Mortal Wkly Rep
24. "Celbenin"-resistant staphylococci
25. Current susceptibilities of staphylococci to glycopeptides determined as part of an international resistance surveillance programme
26. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linezolid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains
27. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistances: Real or perceived?
28. Antimicrobial activity and spectrum of SCH27899 (Ziracin) tested against gram-positive species including recommendations for routine susceptibility testing methods and quality control
29. Staphylococcus aureus and vancomycin: The sequel
30. Tolerance of Staphylococcus epidermidis grown from indwelling vascular catheters to antimicrobial agents
31. Extraction of a highly potent penicillin inactivator from penicillin-resistant staphylococci
32. Emergence of ciprofloxacin resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin
33. Prevalence of fluoroquinolone resistance in Europe
34. Increasing resistance among Staphylococcus epidermidis isolates in a large teaching hospital over a 12 year period
35. Antimicrobial resistance in hospital organisms and its relation to antibiotic use
36. Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus
37. National Nosocomial Infections Surveillance (NNIS) Report; Data summary from October 1986-April 1996
38. Bacterial resistance to fluoroquinolones
39. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus
40. Micrococcus poisoning
41. Methicillin-resistant Staphylococcal aureus in U.S. hospitals, 1975-1991
42. Activity of glycopeptides in combination with amikacin or rifampin against Staphylococcus epidermidis biofilms or plastic catheters
43. Current and future management of infections due to methicillin-resistant staphylococci: The role of quinupristin/dalfopristin
44. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)
45. Bacterial pathogens isolated from patients with bloodstream infections: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)
46. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital
47. Staphylococcus epidermidis: Emerging resistance and need for alternative agents
48. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infection: A randomized, double-blind trial
49. Antibiotics and prevention of microbial colonization of catheters
50. Impact of central venous catheter removal on the recurrence of catheter-related coagulase-negative staphylococcal bacteremia
51. Alternatives to vancomycin in treating methicillin-resistant Staphylococcus aureus infections
52. Recommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC)
53. Methicillin-resistant Staphylococcus aureus (MRSA) in the community: Who's watching?
54. Coagulase negative staphylococci: Pathogens associated with medical progress
55. Comparative in vitro activities and post-antibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis and Enterococcus faecium
56. Antimicrobial resistance in key bloodstream bacterial isolates: Electronic surveillance with the Surveillance Network Database - USA
57. Major trends in the microbial etiology of nosocomial infection
58. Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control
59. European survey of glycopeptide susceptibility in Staphylococcus spp.
60. Susceptibility of respiratory strains of Staphylococcus aureus to fifteen antibiotics: Results of a collaborative surveillance study (1992-1993)
61. New guidelines for the antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis
62. Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against gram-positive bacteria
63. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection
64. Inhibition of cell wall turnover and autolysis by vancomycin in a highly-vancomycin-resistant mutant of Staphylococcus aureus
65. Decreased antimicrobial resistance after changes in antibiotic use
66. Emergence of vancomycin resistance in Staphylococcus aureus
67. Bacterial resistance to tetracycline: Mechanisms, transfer, and clinical significance
68. Predominant pathogens found in the European Prevalence of Infection in Intensive Care study
69. Clinical experience with linezolid in a community hospital setting
70. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides
71. The prevalence of nosocomial infection in intensive care unit in Europe: Results of the European Prevalence of Infection in Intensive Care (EPIC) study
72. Antibiotic resistance in staphylococci in Europe
73. Methicillin-resistant Staphylococcus aureus in Europe
74. Development of new antibiotic resistance in methicillin-resistant but not methicillin-susceptible Staphylococcus aureus
75. Staphylococcus aureus (including toxic shock syndrome)
76. Vancomycin-resistant Staphylococcus aureus: Infection control considerations
77. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms
78. The comparative efficacy and safety of teicoplanin and vancomycin
79. Current perspectives on glycopeptide resistance